{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:17:35Z","timestamp":1787872655336,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejso.2026.111981","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T06:50:41Z","timestamp":1782543041000},"page":"111981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study"],"prefix":"10.1016","volume":"52","author":[{"given":"Hongkun","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanbing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixiong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2026.111981_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192388","article-title":"GEIS Guidelines for gastrointestinal stromal tumors","volume":"15","author":"Serrano","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"5350","key":"10.1016\/j.ejso.2026.111981_bib2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"5607","key":"10.1016\/j.ejso.2026.111981_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.ejso.2026.111981_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"issue":"9669","key":"10.1016\/j.ejso.2026.111981_bib5","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"DeMatteo","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejso.2026.111981_bib6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.ejso.2008.11.005","article-title":"Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)","volume":"35","author":"Fiore","year":"2009","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2026.111981_bib7","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2026.111981_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2407-11-72","article-title":"Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial","volume":"11","author":"Blesius","year":"2011","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.ejso.2026.111981_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3390\/cancers13040586","article-title":"Preservation of organ function in locally advanced non-metastatic gastrointestinal stromal tumors (GIST) of the stomach by neoadjuvant imatinib therapy","volume":"13","author":"Vassos","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15_suppl","key":"10.1016\/j.ejso.2026.111981_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.10031","article-title":"Neoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors","volume":"30","author":"Hohenberger","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10.1016\/j.ejso.2026.111981_bib11","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.ejso.2026.111981_bib12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejso.2026.111981_bib13","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2026.111981_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113439","article-title":"Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: a phase 2, multicenter, randomized, open-label study in China","volume":"196","author":"Li","year":"2024","journal-title":"European Journal of Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2026.111981_bib15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111981_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO\u2013EURACAN\u2013GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111981_bib17","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10120-023-01381-6","article-title":"Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours","volume":"26","author":"Naito","year":"2023","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.ejso.2026.111981_bib18","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s11912-025-01636-8","article-title":"Gastrointestinal stromal tumors","volume":"27","author":"Strauss","year":"2025","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ejso.2026.111981_bib19","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA, J Am Med Assoc"},{"issue":"12","key":"10.1016\/j.ejso.2026.111981_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.annonc.2024.08.2343","article-title":"A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse","volume":"35","author":"Blay","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111981_bib21","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4143\/crt.2021.1040","article-title":"Adjuvant imatinib treatment for 5 years versus 3 years in patients with ruptured localized gastrointestinal stromal tumor: a retrospective analysis","volume":"54","author":"Kang","year":"2022","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejso.2026.111981_bib22","article-title":"Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: a multi-center cohort study","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.ejso.2026.111981_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110473","article-title":"A novel risk score after neoadjuvant imatinib predicts relapse-free survival in patients with gastrointestinal stromal tumours (GIST)","volume":"51","author":"Pozas","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.111981_bib24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","article-title":"Long-Term results from a randomized phase II trial of Standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT","volume":"26","author":"Blanke","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111981_bib25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.ejso.2020.08.004","article-title":"The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice","volume":"47","author":"Rutkowski","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.111981_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ctrv.2013.07.005","article-title":"Adherence to imatinib therapy in patients with gastrointestinal stromal tumors","volume":"40","author":"Blay","year":"2014","journal-title":"Cancer Treat Rev"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:33:10Z","timestamp":1787869990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0748798326006001"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111981","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of perioperative targeted therapy duration on prognosis in patients with gastrointestinal stromal tumors undergoing neoadjuvant imatinib therapy: A nationwide retrospective study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111981"}}